News Sentiment

PACB sentiment intelligence

Pacific Biosciences of California news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 1.56 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

78/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-7.1% over one week, +19.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 78/100 classification
One-week reaction -7.1% Price reacting lower
Trend fit Trend inactive 19.1% over four weeks
Fair value -51.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 28
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 20
TradingView 8
www.marketscreener.com 4
Quartr 4
Stock Titan 2
Investing.com 2
StockStory 2
MarketBeat 1

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 20
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
www.marketscreener.com Direct company coverage

PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026

PacBio (NASDAQ: PACB) announced it will hold a quarterly conference call to discuss its second-quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time. The call will be webcast and accessible via the company's investor relations website. This call w

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 20:12
Source
www.marketscreener.com
Stock Titan Direct company coverage

PacBio’s next earnings update will stream live Aug. 5

PacBio (NASDAQ: PACB) announced that it will host a quarterly conference call on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time, to discuss its second quarter 2026 financial results. Investors can access the live webcast or replay via PacBio's investor relations website or

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 20:12
Source
Stock Titan
Market source Direct company coverage

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know

Pacific Biosciences of California (PACB) shares dropped 4.49% recently, underperforming the broader market despite a 19.08% gain over the past month. The company is expected to report an EPS of -$0.14 and revenue of $42.1 million in its upcoming earnings, with analysts maintainin

Tone
Negative 40/100
Event
Earnings
Published
13 Jul 2026 22:10
Source
Market source
Quartr Direct company coverage

Pacific Biosciences (PACB) Proxy filing Summary

This article summarizes Pacific Biosciences' (PACB) proxy filing, highlighting its focus on advancing genomics through HiFi long-read sequencing technology. The company launched two sequencers, Vega and Revio, and its proxy proposals include electing directors, ratifying auditors

Tone
Positive 77/100
Event
Market update
Published
13 Jul 2026 20:19
Source
Quartr
TradingView Direct company coverage

Pacific director Christopher M. Smith resigns from board

Christopher M. Smith has resigned from the board of Pacific Biosciences of California (PACB), effective July 8, 2026. The reason for his resignation and details about a replacement were not disclosed. This information is based on an SEC 8-K filing from July 9, 2026.

Tone
Negative 40/100
Event
Market update
Published
09 Jul 2026 21:11
Source
TradingView
Stock Titan Direct company coverage

[8-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Reports Material Event

Pacific Biosciences of California, Inc. (PACB) filed an 8-K report announcing the immediate resignation of board member Christopher M. Smith, effective July 8, 2026. The company stated there was no disagreement with Mr. Smith regarding its operations, policies, or practices that

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:11
Source
Stock Titan
Quartr Direct company coverage

Pacific Biosciences (PACB) Goldman Sachs 46th Annual Global Healthcare Conference summary

Pacific Biosciences (PACB) presented a summary at the Goldman Sachs 46th Annual Global Healthcare Conference, highlighting advancements in its HiFi long-read sequencing technology and the Revio platform, which has significantly reduced genome sequencing costs. The company achieve

Tone
Positive 74/100
Event
Market update
Published
08 Jul 2026 20:41
Source
Quartr
Quartr Direct company coverage

Pacific Biosciences (PACB) Q3 2025 earnings summary

Pacific Biosciences (PACB) reported Q3 2025 revenue of $38.4 million, driven by record consumables sales, despite a decline in instrument revenue. The company achieved a non-GAAP gross profit of $16.2 million (42% margin) and narrowed its non-GAAP net loss to $36.8 million. PACB

Tone
Positive 65/100
Event
Earnings
Published
08 Jul 2026 20:41
Source
Quartr
Quartr Direct company coverage

Pacific Biosciences (PACB) Q1 2025 earnings summary

Pacific Biosciences (PACB) reported Q1 2025 revenue of $37.2M, a decrease from Q1 2024, despite record consumables growth, due to lower instrument sales. The company has initiated a major restructuring to focus on long-read sequencing and reduce operating expenses, lowering its f

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 08:40
Source
Quartr
AD HOC NEWS Direct company coverage

Pacific Biosciences updates its sequencing strategy. Investors watch long-read technology

Pacific Biosciences is refining its strategy in the genomic sequencing market by focusing on high-accuracy long-read technologies, which are gaining importance across research and clinical applications. The company generates revenue by selling instruments, consumables, and servic

Tone
Positive 67/100
Event
Earnings
Published
07 Jul 2026 15:10
Source
AD HOC NEWS
Investing.com Direct company coverage

Earnings call transcript: Pacific Biosciences reports Q1 2026 earnings beat

Pacific Biosciences (PACB) reported a mixed Q1 2026, beating EPS expectations with -$0.12 against a forecasted -$0.14, but missing revenue targets at $37.2 million compared to an anticipated $39.98 million. Despite flat year-over-year revenue, consumables grew by 9%, offsetting a

Tone
Positive 60/100
Event
Earnings
Published
05 Jul 2026 21:42
Source
Investing.com
Investing.com Direct company coverage

Pacific Biosciences Q1 2026 slides: consumables hit record amid product launch

Pacific Biosciences (NASDAQ:PACB) reported a mixed Q1 2026, beating earnings expectations but missing on revenue. The company saw record consumables revenue, driven by clinical adoption, while instrument sales declined. A significant upcoming product launch, SPRQ-Nx, is expected

Tone
Positive 63/100
Event
Earnings
Published
05 Jul 2026 18:42
Source
Investing.com
Insider Monkey Direct company coverage

Is Pacific Biosciences (PACB) The Best Rising Penny Stock?

Pacific Biosciences of California, Inc. (PACB) has seen significant gains recently, rising over 12% in the past month and 35% since the launch of SPRQ-Nx sequencing chemistry. Wall Street analysts predict a 59% upside. The company's new chemistry reduces genome sequencing costs a

Tone
Positive 75/100
Event
Market update
Published
03 Jul 2026 13:10
Source
Insider Monkey
Market source Direct company coverage

Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why

Pacific Biosciences of California (PACB) stock dropped 2.89% to $1.68, underperforming major market indices on a day led by gains. Despite this, the company's shares have risen 9.49% over the past month, surpassing its sector and the S&P 500. Investors are now awaiting its financ

Tone
Negative 39/100
Event
Market update
Published
30 Jun 2026 22:10
Source
Market source
www.marketscreener.com Direct company coverage

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell Small Cap Comp Growth Benchmark

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) has been added to the Russell Small Cap Comp Growth Benchmark. This addition highlights the company's position as a life science technology firm specializing in designing and manufacturing sequencing solutions, including its

Tone
Positive 75/100
Event
Market update
Published
29 Jun 2026 20:11
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000 Growth Benchmark

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) has been added to the Russell 3000 Growth Benchmark. This news, published on June 28, 2026, marks the company's inclusion in several Russell growth indices, including the Russell Small Cap Comp Growth, Russell 2500 Growth, a

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 16:39
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000E Growth Benchmark

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) has been added to the Russell 3000E Growth Benchmark. The company, a life sciences technology firm, specializes in designing and manufacturing sequencing solutions, primarily known for its HiFi long-read sequencing technolog

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 03:40
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBITDA forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB

This article provides financial information for Pacific Biosciences of California, Inc. (NASDAQ: PACB), specifically focusing on its enterprise value to EBITDA forward. It indicates the stock is listed on the Nasdaq Stock Market and that the market was closed at the time the data

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 06:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB

This article provides access to the "Price to sales forward" financial data for Pacific Biosciences of California, Inc. (NASDAQ: PACB) on the TradingView platform. It highlights that this specific financial metric is unavailable at the moment, indicating either no current data en

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 17:41
Source
TradingView
Market source Direct company coverage

PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions

Analysts have issued mixed changes to their price targets for Pacific Biosciences of California (PACB), with some increasing targets by $0.50 and others trimming them. These adjustments reflect differing views on the company's valuation and ability to meet expectations. While the

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 09:07
Source
Market source
TradingView Direct company coverage

Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB

This article provides a financial data point for Pacific Biosciences of California, Inc. (NASDAQ: PACB), specifically its enterprise value to EBIT forward. The content appears to be a stub or a data point from a financial platform like TradingView, indicating no further details a

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 13:10
Source
TradingView
TradingView Direct company coverage

Pacific Biosciences of California, Inc. Actuals & Estimates (NASDAQ:PACB)

This article provides an overview of Pacific Biosciences of California, Inc. (NASDAQ: PACB), including its current stock price, historical performance, analyst forecasts, and key financial metrics. It highlights recent stock price movements, earnings results, revenue figures, mar

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Pacific Biosciences of California, Inc. – FWB:P09

This article displays the "Enterprise value to revenue forward" metric for Pacific Biosciences of California, Inc. (FWB:P09) on the TradingView platform. It provides financial data for the company sourced from ICE Data Services and FactSet for the Frankfurt Stock Exchange. The co

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – FWB:P09

This article focuses on the enterprise value to EBIT forward metric for Pacific Biosciences of California, Inc. (FWB:P09) as displayed on the TradingView platform. It provides a snapshot of the company's financial data on the Frankfurt Stock Exchange within the Health Technology

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 21:41
Source
TradingView
StocksToTrade Direct company coverage

PACB Stock Gains Focus As New Sequencing Tech Slashes Genome Costs

Pacific Biosciences of California Inc. (PACB) stock has rallied due to its new SPRQ-Nx sequencing chemistry and multi-use SMRT Cells for the Revio HiFi platform, drastically cutting the cost of human genome sequencing to about $345. This innovation, coupled with improved data qua

Tone
Positive 71/100
Event
Market update
Published
25 Jun 2026 17:41
Source
StocksToTrade
TradingView Direct company coverage

PACB Forecast — Price Target — Prediction for 2027

This article provides a forecast for Pacific Biosciences of California, Inc. (PACB) stock, including analyst price targets and predictions for 2027. It details the current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also inc

Tone
Positive 63/100
Event
Analyst action
Published
25 Jun 2026 17:41
Source
TradingView